Yeniocak Selman, Kalkan Asım, Yamanoğlu Adnan, Öztürk Semi, Söğüt Özgür, Metiner Merve
Department of Emergency Medicine, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Department of Emergency Medicine, Okmeydanı Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Turk J Emerg Med. 2021 Oct 29;21(4):198-204. doi: 10.4103/2452-2473.329634. eCollection 2021 Oct-Dec.
Limited clinical studies have investigated the effects of synthetic cannabinoids (SCs) on the cardiovascular system (CVS). The aim of this study was to evaluate the effects of SCs on the CVS.
The patient group of this single-center, prospective, case-control study consisted of adult patients presenting to the emergency department (ED) with symptoms of SC use. Vital signs and electrocardiogram (ECG) after use of SC of patients were followed. A control group with a similar number of patients and patient demographics were formed following the patient admission process. Pulse rate, arterial blood pressure (ABP), and ECG of patient and control groups were compared using Mann-Whitney U and Chi-squared tests.
A total of 148 people were included in the study, 74 in the patient group and 74 in the control group. Systolic and diastolic ABPs of patient group were statistically significantly lower than those of the control group ( < 0.001). P-wave width and amplitude in the patient group were significantly higher compared to the control group (: 0.027 and : 0.004, respectively). QRS width on patient group ECGs was significantly higher than in the control group, while T-wave amplitude was significantly lower (: 0.045 and < 0.001, respectively). ST elevation was seen in 12 (16.2%) subjects in the patient group, while no ST elevation was seen in the control group ( < 0.001).
SCs can reduce systemic tension and SCs may cause changes in ECG, especially wave, ST segment, T wave, and QRS. Further large-scale studies are needed to show whether these changes are associated with fatal arrhythmias or myocardial infarction.
有限的临床研究调查了合成大麻素（SCs）对心血管系统（CVS）的影响。本研究的目的是评估SCs对CVS的影响。
这项单中心、前瞻性、病例对照研究的患者组由因使用SCs出现症状而就诊于急诊科（ED）的成年患者组成。对患者使用SCs后的生命体征和心电图（ECG）进行跟踪。在患者入院后，组建了一个患者数量和人口统计学特征相似的对照组。使用曼-惠特尼U检验和卡方检验比较患者组和对照组的脉搏率、动脉血压（ABP）和ECG。
本研究共纳入148人，患者组74人，对照组74人。患者组的收缩压和舒张压在统计学上显著低于对照组（<0.001）。与对照组相比，患者组的P波宽度和振幅显著更高（分别为：0.027和：0.004）。患者组ECG的QRS宽度显著高于对照组，而T波振幅显著更低（分别为：0.045和<0.001）。患者组中有12名（16.2%）受试者出现ST段抬高，而对照组未出现ST段抬高（<0.001）。
SCs可降低全身张力，并且SCs可能会引起ECG变化，尤其是P波、ST段、T波和QRS波。需要进一步的大规模研究来表明这些变化是否与致命性心律失常或心肌梗死有关。
